Tectonic Therapeutic Announces Start of First Clinical Program for GPCR-Targeted Biologic

TX45, an Fc-Relaxin fusion with best-in-class properties now in dose-escalation studies in human subjects

BOSTON--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. a biotechnology company transforming the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors), today announced it completed dosing of the first human cohort in its Fc-relaxin fusion program targeting the RXFP1 receptor.

“The start of our first-in-human study is a critical and exciting milestone. We look forward to seeing the potential of relaxin biology realized in patients,” said Alise Reicin, MD, President and Chief Executive Officer, Tectonic Therapeutic.

Relaxin, through its action as an agonist of the RXFP1 receptor, produces a unique and diverse range of biological effects that include pulmonary and systemic vasodilation, tissue remodeling / fibrosis reversal and reduction of inflammation. Because of these features, it offers a similarly broad range of potential therapeutic applications with significant benefits expected in cardio-pulmonary diseases. Known as a “pregnancy hormone,” relaxin is upregulated during pregnancy to help the expectant mother’s cardiovascular system meet the increased demand from the developing fetus, and to remodel tissues and musculoskeletal structures involved in childbirth.

Tectonic’s TX000045 Fc-relaxin fusion protein (“TX45”) is a potential best-in-class agent, resulting from protein engineering efforts to overcome the human hormone’s biophysical property limitations and achieve optimal pharmacokinetic, target engagement and developability properties. Following completion of dose escalation safety studies in healthy volunteers, continued development of TX45 will focus on addressing areas of very high unmet need in cardio-pulmonary indications.

“TX45 could be a potentially transformative therapy for a vast number of patients with cardiovascular diseases,” said Tim Springer, PhD, Co-Founder of Tectonic and Latham Family Professor, Harvard Medical School and Professor of Medicine, Children’s Hospital Boston. He also added, "TX45 is exemplary of the company’s ability to execute in the development of novel GPCR-targeted biologics. We look forward to future clinical programs emerging from Tectonic’s platform.”

About Tectonic Therapeutic

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting GPCRs to develop novel therapies for patients inadequately served by current treatments. With its proprietary GEODe platform, Tectonic aims to unlock the therapeutic utility of the most difficult receptors in the class, where small molecule pharmacology may be intractable.

For more information, please visit www.tectonictx.com, or follow us on LinkedIn.